Aprea Therapeutics Announces Interim Results From the Ongoing First-in-human Phase 1 Study of WEE1 Inhibitor APR-1051 in Patients with Advanced Solid Tumors (ACESOT-1051) at the 38th EORTC-NCI-AACR Symposium in Barcelona
Globe Newswire•20/11/2026•09:00 ET
0
Key Highlights
- ➤56 patients treated; two partial responses and five durable stable-disease cases observed
- ➤Confirmed uterine carcinosarcoma response ongoing beyond 10 months at data cutoff
- ➤WEE1 target engagement reached 84% of evaluable patients across multiple doses
- ➤One dose-limiting toxicity occurred; Grade 3 pneumonitis affected two patients
- ➤Aprea plans focused enrollment in uterine serous and cyclin E-overexpressing ovarian cancers
Expert Statements
Oren Gilad, President and Chief Executive Officer of Aprea
“These interim results reinforce our focus on advancing APR-1051 in biomarker selected cancers”
Oren Gilad, President and Chief Executive Officer of Aprea
“The ongoing confirmed partial response, additional unconfirmed partial response, and prolonged stable disease observed in multiple heavily pre-treated patients provide encouraging early evidence of single-agent clinical activity, supported by WEE1 target engagement and pharmacokinetics compatible with continuous once-daily dosing.”
Oren Gilad, President and Chief Executive Officer of Aprea
“Our strategy is to transition from a broad, biomarker-enriched Phase 1 study toward more focused expansion cohorts in patient populations most likely to benefit from APR-1051.”
Oren Gilad, President and Chief Executive Officer of Aprea
“Our goal is to evaluate whether APR-1051 can produce clinically meaningful and durable responses in a well-defined patient population with significant unmet medical need.”
Eugene Kennedy, MD, Chief Medical Advisor at Aprea
“Patients with advanced uterine and platinum-resistant ovarian cancers need additional treatment options after progression on available therapies”
Eugene Kennedy, MD, Chief Medical Advisor at Aprea
“The observed target engagement and prolonged treatment duration in a patient with a confirmed response provide a rationale to continue evaluating APR-1051 in carefully selected patients.”
Eugene Kennedy, MD, Chief Medical Advisor at Aprea
“Expanding enrollment in biologically selected populations will help us better characterize clinical activity, assess the consistency of responses and further evaluate tolerability.”
Eugene Kennedy, MD, Chief Medical Advisor at Aprea
“These data will be important for optimizing dose selection and informing subsequent development.”
Safety profile to date with continuous daily dosing supports continued dose optimization and clinical development
Pharmacodynamic data demonstrate WEE1 target engagement across multiple doses, pharmacokinetics support once-daily administration
Get started
Create a free account to read the full story.
